Data from a new investigational drug that could alter the standard treatment for a rare blood disease suggests it has the potential to delay or prevent anemia and the need for intrauterine blood transfusions in babies who are at high risk for the condition, known as Hemolytic Disease of the Fetus and Newborn (HDFN).